NINLARO™ (ixazomib) Receives Conditional Approval from the Europe
Approval Based on TOURMALINE-MM1 Study Results, Which Demonstrated Statistic...
2016-11-29
文传商讯
Takeda Receives Positive CHMP Opinion for Conditional Approval of NINLA
− If authorized, NINLARO will provide a new treatment option for Europ...
2016-09-20
文传商讯
Takeda Launches Largest Pharmaceutical Company-Sponsored Global Observa
Open-source, collaborative study initiated to advance understanding of real-...
2016-09-02
文传商讯
Takeda Receives Marketing Authorization in Canada for NINLARO (ixazomib
-NINLARO is the first and only oral proteasome inhibitor approved to provide...
2016-08-09
文传商讯
